---
$id: https://graph.org.ai/products/commodity/51131731
$type: Product
source: UNSPSC
code: "51131731"
title: "Setipafant"
class: "51131700"
classTitle: "Thrombolytic drugs and platelet aggregation inhibitors"
family: "51130000"
familyTitle: "Hematolic drugs"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Setipafant

**UNSPSC Code**: 51131731
**Class**: [Thrombolytic drugs and platelet aggregation inhibitors](Thrombolytic drugs and platelet aggregation inhibitors.mdx)
**Family**: [Hematolic drugs](../Hematolic drugs.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes an antiplatelet agent with the molecular formula C26H23ClN6O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UFN2Q54HS6, chemically known as 6-(o-chlorophenyl)-7,10-dihydro-1-methyl-4h-pyrido(4,3:4,5)thieno(3,2-f)-s-triazolo(4,3-a)(1,4)diazepine-9(8h)-carbox-p-anisidide but generally known as setipafant, which bears US NIH Compound Identifier 65968. European Medicines Agency schedules Setipafant in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10502MIG. The term SETIPAFANT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, No. 3, 1995, List 35). SETIPAFANT is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule setipafant under HS 29349990 and SITC 51579. As of Q4 2014, SETIPAFANT remains the US FDA Preferred Term for this commodity. Setipafant bears US NLM identifiers UMLS ID C2699291 and NCI Concept Code C76402. SMILES: CLC1C(C2=NCC3N(C4SC5C(CCN(C5)C(=O)NC5CCC(OC)CC5)C24)C(NN3)C)CCCC1.

